货号:A1329181 同义名: 奥拉布替尼 / ICP-022
Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | BTK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CGI-1746 |
+++
BTK, IC50: 1.9 nM |
98% | |||||||||||||||||
Spebrutinib |
++++
BTK, IC50: <0.5 nM |
98+% | |||||||||||||||||
Acalabrutinib |
++
BTK, IC50: 3nM |
98% | |||||||||||||||||
CNX-774 |
+++
BTK, IC50: <1 nM |
99%+ | |||||||||||||||||
Ibrutinib |
++++
BTK, IC50: 0.5 nM |
98% | |||||||||||||||||
ONO-4059 analog |
+
BTK, IC50: 23.9 nM |
98% | |||||||||||||||||
RN486 |
++
BTK, IC50: 4 nM |
99%+ | |||||||||||||||||
(Z)-LFM-A13 |
+
BTK, Ki: 1.4 μM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Orelabrutinib (ICP-022) acts as a potent, orally active, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), exhibiting potential antineoplastic properties. It blocks the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-dependent activation of downstream survival pathways, thereby inhibiting the proliferation of malignant B-cells that overexpress BTK [1][2]. |
体内研究 | Upon dosing, Orelabrutinib (ICP-022) effectively binds to and suppresses BTK activity, thereby impeding the activation of the B-cell antigen receptor (BCR) signaling pathway and downstream survival pathways mediated by BTK. Consequently, the proliferation of malignant B-cells, characterized by overexpression of BTK, is inhibited [2]. |
体外研究 | Orelabrutinib (ICP-022) demonstrates superior bioavailability compared to other BTK inhibitors, owing to its proprietary formulation [1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.34mL 0.47mL 0.23mL |
11.70mL 2.34mL 1.17mL |
23.39mL 4.68mL 2.34mL |
CAS号 | 1655504-04-3 |
分子式 | C26H25N3O3 |
分子量 | 427.495 |
别名 | 奥拉布替尼 ;ICP-022 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 105 mg/mL(245.62 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |